DSpace Repository

Antifibrinolytic therapy to reduce haemoptysis from any cause

Show simple item record

dc.contributor.author Prutsky, Gabriela
dc.contributor.author Domecq, Juan Pablo
dc.contributor.author Salazar, Carlos A.
dc.contributor.author Accinelli, Roberto
dc.date.accessioned 2019-02-22T14:56:09Z
dc.date.available 2019-02-22T14:56:09Z
dc.date.issued 2016
dc.identifier.uri https://hdl.handle.net/20.500.12866/5846
dc.description.abstract Background: Haemoptysis is a common pathology around the world, occurring with more frequency in low-income countries. It has different etiologies, many of which have infectious characteristics. Antifibrinolytic agents are commonly used to manage bleeding from different sources, but their usefulness in pulmonology is unclear. Objectives: To evaluate the effectiveness and safety of antifibrinolytic agents in reducing the volume and duration of haemoptysis in adult and paediatric patients. Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE) in The Cochrane Library, EMBASE and LILACS for publications that describe randomized controlled trials (RCTs) of antifibrinolytic therapy in patients presenting with haemoptysis. We also performed an independent search in MEDLINE for relevant trials not yet included in CENTRAL or DARE. Searches are up to date to the 19th September 2016. We conducted electronic and manual searches of relevant national and international journals. We reviewed the reference lists of included studies to locate relevant randomized controlled trials (RCTs). An additional search was carried out to find unpublished RCTs. Selection criteria: We included RCTs designed to evaluate the effectiveness and safety of antifibrinolytic agents in reducing haemoptysis in adult and paediatric patients of both genders presenting with haemoptysis of any etiology and severity. The intervention of interest was the administration of antifibrinolytic agents compared with placebo or no treatment. Data collection and analysis: All reviewers independently assessed methodological quality and extracted data tables pre-designed for this review. Main results: The electronic literature search identified 1 original study that met the eligibility criteria. One unpublished study was also identified through manual searches. Therefore two randomized controlled trials met the inclusion criteria: Tscheikuna 2002 (via electronic searches) and Ruiz 1994 (via manual searches). Tscheikuna 2002, a double-blind RCT performed in Thailand, evaluated the effectiveness of tranexamic acid (TXA, an antifibrinolytic agent) administered orally in 46 hospital in-and outpatients with haemoptysis of various etiologies. Ruiz 1994, a double-blind RCT performed in Peru, evaluated the effectiveness of intravenous TXA in 24 hospitalised patients presenting with haemoptysis secondary to tuberculosis. Pooled together, results demonstrated a significant reduction in bleeding time between patients receiving TXA and patients receiving placebo with a weighted mean difference (WMD) of -19.47 (95% CI -26.90 to -12.03 hours), but with high heterogeneity (I-2 = 52%). TXA did not affect remission of haemoptysis evaluated at seven days after the start of treatment. Adverse effects caused by the drug's mechanism of action were not reported. There was no significant difference in the incidence of mild side effects between active and placebo groups (OR 3.13, 95% CI 0.80 to 12.24). Authors' conclusions: There is insufficient evidence to judge whether antifibrinolytics should be used to treat haemoptysis from any cause, though limited evidence suggests they may reduce the duration of bleeding. en_US
dc.language.iso eng
dc.publisher Cochrane Collaboration
dc.relation.ispartof urn:issn:1469-493X
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Peru en_US
dc.subject Adult en_US
dc.subject Humans en_US
dc.subject Thailand en_US
dc.subject etiology en_US
dc.subject Administration en_US
dc.subject Antifibrinolytic Agents [administration & dosage en_US
dc.subject Hemoptysis [drug therapy en_US
dc.subject Injections en_US
dc.subject Intravenous en_US
dc.subject mortality] en_US
dc.subject Oral en_US
dc.subject RandomizedControlledTrials as Topic en_US
dc.subject therapeutic use] en_US
dc.subject Tranexamic Acid [administration& dosage en_US
dc.title Antifibrinolytic therapy to reduce haemoptysis from any cause en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1002/14651858.CD008711.pub3
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics